eClinical Technology and Industy News

Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2

  • ELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in vivo that were maintained for >5 months after vaccination
  • Vaccine responses were highly cross-reactive to SARS-CoV-2 variants of concern
  • Antibody responses favored TH1 isotypes with titers 265-fold higher than natural convalescent patient COVID-19 responses
  • Results suggest delivery of AMP-CpG to lymph nodes could be applied to rapid development of prophylactic or therapeutic vaccine candidates targeting a variety of disease-specific antigens

CAMBRIDGE Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit, being held virtually on September 20-22, 2021.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives